Skip to main content
Journal cover image

Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma.

Publication ,  Journal Article
Ajani, JA; Pazdur, R; Winn, RJ; Abbruzzese, JL; Levin, B; Wiseman, C; Lenado-Lee, MA; Patt, YZ; Krakoff, IH
Published in: Invest New Drugs
August 1991

In a phase II study, 18 patients with advanced gastric carcinoma were treated with intravenous 6-thioguanine. A 30-minute infusion of 55 mg/m2 (starting dose) was administered once a day for 5 consecutive days, the courses being repeated every 5 weeks. A median of 2 courses (range, 1-4) was administered. Among the 18 patients, 17 having measurable cancer and optimum follow-up were fully assessable for response. None of the patients achieved a complete or partial response. One patient achieved a transient minor response (15 weeks) of the primary gastric carcinoma but the metastatic carcinoma was unchanged. One patient had no change in his measurable carcinoma, and the other 15 patients had progressive disease while receiving intravenous-6-thioguanine. Myelosuppression, although frequent, was mild to moderate at these doses and did not result in significant morbidity. Nonhematologic toxicities were also mild. Our data suggest that intravenous 6-thioguanine given at this schedule is ineffective in previously untreated patients with advanced gastric carcinoma.

Duke Scholars

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

August 1991

Volume

9

Issue

3

Start / End Page

257 / 259

Location

United States

Related Subject Headings

  • Thioguanine
  • Stomach Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
  • Female
  • Drug Evaluation
  • Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ajani, J. A., Pazdur, R., Winn, R. J., Abbruzzese, J. L., Levin, B., Wiseman, C., … Krakoff, I. H. (1991). Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. Invest New Drugs, 9(3), 257–259. https://doi.org/10.1007/BF00176979
Ajani, J. A., R. Pazdur, R. J. Winn, J. L. Abbruzzese, B. Levin, C. Wiseman, M. A. Lenado-Lee, Y. Z. Patt, and I. H. Krakoff. “Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma.Invest New Drugs 9, no. 3 (August 1991): 257–59. https://doi.org/10.1007/BF00176979.
Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Wiseman C, et al. Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. Invest New Drugs. 1991 Aug;9(3):257–9.
Ajani, J. A., et al. “Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma.Invest New Drugs, vol. 9, no. 3, Aug. 1991, pp. 257–59. Pubmed, doi:10.1007/BF00176979.
Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Wiseman C, Lenado-Lee MA, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. Invest New Drugs. 1991 Aug;9(3):257–259.
Journal cover image

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

August 1991

Volume

9

Issue

3

Start / End Page

257 / 259

Location

United States

Related Subject Headings

  • Thioguanine
  • Stomach Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
  • Female
  • Drug Evaluation
  • Aged